These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1934591)

  • 1. Enhanced serum levels of soluble HLA class I molecules are induced by treatment with recombinant interferon-gamma (IFN-gamma).
    Aulitzky WE; Grosse-Wilde H; Westhoff U; Tilg H; Aulitzky W; Gastl G; Herold M; Huber C
    Clin Exp Immunol; 1991 Nov; 86(2):236-9. PubMed ID: 1934591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged interferon-gamma application by subcutaneous infusion in cancer patients: differential response of serum CD14, neopterin, and monocyte HLA class I and II antigens.
    Landmann R; Ludwig C; Wesp M; Fisscher A; Obrist R; Knüsli C; Denz H; Obrecht JP
    J Interferon Res; 1992 Apr; 12(2):103-11. PubMed ID: 1374454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-gamma for the treatment of metastatic renal cancer: dose-dependent stimulation and downregulation of beta-2 microglobulin and neopterin responses.
    Aulitzky W; Gastl G; Aulitzky WE; Nachbaur K; Lanske B; Kemmler G; Flener R; Frick J; Huber C
    Immunobiology; 1987 Dec; 176(1-2):85-95. PubMed ID: 3129362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Production of soluble HLA-class-I molecules by IFN-gamma-induced colon-adenocarcinoma cells.
    Le J; Hua JC
    Int J Cancer; 1995 Feb; 60(4):576-81. PubMed ID: 7829274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavior of soluble HLA class I antigens in patients with chronic hepatitis C during interferon therapy: an early predictor marker of response?
    Puppo F; Picciotto A; Brenci S; Varagona G; Scudeletti M; Ghio M; Balestra V; Celle G; Indiveri F
    J Clin Immunol; 1995 Jul; 15(4):179-84. PubMed ID: 7593464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevation of 2',5'-oligoadenylate synthetase activity and HLA-I associated beta 2-microglobulin in response to recombinant interferon-gamma administration in chronic HBeAg-positive hepatitis.
    Quiroga JA; Mora I; Porres JC; Carreño V
    J Interferon Res; 1988 Dec; 8(6):755-63. PubMed ID: 3148006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induced proteins in human peripheral mononuclear cells over a range of clinically tolerable doses of interferon-gamma.
    Paulnock DM; Havlin KA; Storer BM; Spear GT; Sielaff KM; Borden EC
    J Interferon Res; 1989 Aug; 9(4):457-73. PubMed ID: 2502586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute effects of single doses of recombinant interferon-gamma on blood cell counts and lymphocyte subsets in patients with advanced renal cell cancer.
    Aulitzky WE; Aulitzky W; Gastl G; Lanske B; Reitter J; Frick J; Tilg H; Berger M; Herold M; Huber C
    J Interferon Res; 1989 Aug; 9(4):425-33. PubMed ID: 2502583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of interferon-gamma-induced major histocompatibility (MHC) and CD14 antigen changes by lipophilic muramyltripeptide MTP-PE in human monocytes.
    Landmann R; Wesp M; Dukor P
    Cell Immunol; 1988 Nov; 117(1):45-55. PubMed ID: 2460255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans.
    Schiller JH; Storer B; Paulnock DM; Brown RR; Datta SP; Witt PL; Borden EC
    J Clin Invest; 1990 Oct; 86(4):1211-21. PubMed ID: 2120284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant interferon-gamma can induce the expression of HLA-DR and -DC on DR-negative melanoma cells and enhance the expression of HLA-ABC and tumor-associated antigens.
    Carrel S; Schmidt-Kessen A; Giuffrè L
    Eur J Immunol; 1985 Feb; 15(2):118-23. PubMed ID: 3918869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of beta 2m-free HLA class I heavy chains in neuroblastoma cell lines.
    Marozzi A; Meneveri R; Bunone G; De Santis C; Lopalco L; Beretta A; Agresti A; Siccardi AG; Della Valle G; Ginelli E
    Scand J Immunol; 1993 Jun; 37(6):661-7. PubMed ID: 8316764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune response induced in small-cell lung cancer by maintenance therapy with interferon gamma.
    Pujol JL; Gibney DJ; Su JQ; Maksymiuk AW; Jett JR
    J Natl Cancer Inst; 1993 Nov; 85(22):1844-50. PubMed ID: 8230265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-gamma modulates HLA class II antigen expression on cultured human thymic epithelial cells.
    Berrih S; Arenzana-Seisdedos F; Cohen S; Devos R; Charron D; Virelizier JL
    J Immunol; 1985 Aug; 135(2):1165-71. PubMed ID: 3925000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma.
    Aulitzky W; Gastl G; Aulitzky WE; Herold M; Kemmler J; Mull B; Frick J; Huber C
    J Clin Oncol; 1989 Dec; 7(12):1875-84. PubMed ID: 2511277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA-DR synthesis induction and expression in HLA-DR-negative carcinoma cell lines of diverse origins by interferon-gamma but not by interferon-beta.
    Shaw AR; Chan JK; Reid S; Seehafer J
    J Natl Cancer Inst; 1985 Jun; 74(6):1261-8. PubMed ID: 3923246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of HLA class I and beta 2-microglobulin on human choriocarcinoma cell lines: induction of HLA class I by interferon-gamma.
    Kato M; Ohashi K; Saji F; Wakimoto A; Tanizawa O
    Placenta; 1991; 12(3):217-26. PubMed ID: 1754572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced serum levels of beta-2-microglobulin, neopterin, and interferon-gamma in patients treated with recombinant tumor necrosis factor-alpha.
    Aulitzky WE; Tilg H; Herold M; Berger M; Vogel W; Judmaier G; Gastl G; Mull B; Flener R; Wiegele J
    J Interferon Res; 1988 Oct; 8(5):655-64. PubMed ID: 3148671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of interferon induction of class I major histocompatibility complex antigen expression by human tumor necrosis factor in small cell lung cancer cell lines.
    Marley GM; Doyle LA; Ordóñez JV; Sisk A; Hussain A; Yen RW
    Cancer Res; 1989 Nov; 49(22):6232-6. PubMed ID: 2553249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.